Talks (317)
LEAP-006 and 008 negative in NSCLC
Sep 22
GALAXY trial and ctDNA/MRD
Sep 19
NSCLC
Sep 19
Breast Ca
Sep 19
esophageal ca
Sep 18
Breast Cancer
Sep 18
Agnostic approvals in oncology 2
Sep 16
Agnostic Drug approvals in oncology
Sep 16
NSCLC
Sep 15
NSCLC
Sep 15
Oncology Economics
Sep 15
NSCLC
Sep 15
NSCLC
Sep 15
ER+ breast cancer Neoadjuvant
Sep 11
yoga in cancer care
Sep 10
HPV OPSCC
Sep 10
Neoadjuvant IO
Sep 07
mesothelioma
Sep 07
COBRA/NRG-005 closed early
Sep 01
Enhertu gets breakthrough designation
Aug 31
Luspatercept approval in MDS
Aug 30
Steroids and immunotherapy response
Aug 30
Divarasib in KRAS G12C mutant tumors
Aug 30
trastuzumab with ram/taxol in GEJ cancer
Aug 29
PROSPECT TRIAL-NEOADJUVANT FOLFOX
Aug 29
GLOW TRIAL
Aug 29
SPOTLIGHT TRIAL
Aug 29
obesity related cancers
Aug 28
melanomas
Aug 28
ctDNA
Aug 28
HER-RAM Trial
Aug 24
DESTINY GASTRIC 02 trial
Aug 24
ATORVASTATIN and Anthracyclines
Aug 24
Divarasib in solid tumors
Aug 24
CABINET trial positive
Aug 24
Anxiety and Depression in Cancer
Aug 21
Anxiety and Depression in Ca pt
Aug 21
AI
Aug 21
FDA approval of TAS-102/bev in mCRC
Aug 20
Melphalan in uveal melanoma
Aug 20
GLOW trial
Aug 20
breast cancer
Aug 20
bladder cancer
Aug 20
Fracking and lymphoma
Aug 20
Cardio fitness
Aug 20
PEMBRO LEN In Non clear cell RCC
Aug 16
EVEREST TRIAL
Aug 16
her2 mutations in breast cancer
Aug 15
pdl1 in tnbc
Aug 15
esr1 mutations
Aug 15
first line therapy in met TNBC
Jul 31
endocrine resistance.
Jul 31
second line therapy in HR pos MBC
Jul 31
neo chemo for tnbc
Jul 31
therapy selections for neo HR pos BC
Jul 31
neo adjuvant therapy in HR pos EBC
Jul 31
Incidences of HCC in the US
Jul 31
How do I approach treating rectal cancer
Jul 31
liver transplantation for mCRC
Jul 31
QUANTAM-First
Jul 30